ReviewMicroorganisms2026
Viral Reactivation in Immunocompetent Critically Ill Patients.
Review in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The course of critically ill patients admitted to the intensive care unit very often may be complicated by viral infections. Latent viruses may reactivate in 'apparently' immunocompetent critically ill patients as consequence of inflammatory and immune dysregulation secondary to critical illness. Evidence suggests that reactivation correlates with worse clinical outcomes, including increased mortality. Highly sensitive molecular diagnostic techniques have enhanced the ability to detect viral pathogens, but still consensus definitions for reactivation and subsequently the discrimination between reactivation and overt infection in critically ill patients are lacking. Despite the progress in detecting viral pathogens, their role in clinical outcomes is obscured. Furthermore, the role of antiviral therapy, either prophylactically/preemptively or as treatment after virus detection, has to be further investigated. The question of whether reactivation is the cause or a surrogate marker of underlying severity of illness has not yet been fully elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.